Study guide
18.2 Viral Serodiagnosis: Hepatitis, EBV, HIV, CMV, Rubella, Measles
ASCP Microbiology Technologist M ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current M(ASCP) Exam Facts 1.2 CAT, Scoring, Retakes, and CMP 1.3 Eligibility Routes and Clinical Experience
2 Preanalytic: Collection and Transport
2.1 Patient Identification and Specimen Labeling 2.2 Specimen Collection, Sterile Technique, and Blood Cultures 2.3 Transport Devices, Atmosphere, Time, and Temperature
3 Preanalytic: Processing, Media, and Incubation
3.1 Prioritization, Rejection, and Specimen Preparation 3.2 Media Types, Components, and Selection 3.3 Inoculation, Incubation Conditions, and Slide Preparation
4 Preanalytic: Stains
4.1 Gram Stain: Procedure, Principle, and Interpretation 4.2 Acid-Fast and Modified Acid-Fast Stains 4.3 KOH, Calcofluor-White, Trichrome, Giemsa, and Acridine Orange
5 Bacteriology: Blood and Bone Marrow
5.1 Blood Culture Systems and Rapid Identification 5.2 Bloodstream Pathogens and Skin Flora Significance 5.3 Endocarditis, Bone Marrow Pathogens, and Pathogenicity
6 Bacteriology: CSF and Sterile Body Fluids
6.1 CSF Sources and Acute Meningitis Pathogens 6.2 Shunt Infections, CSF Correlates, Antigen and Molecular Methods 6.3 Sterile Body Fluids: Pathogens, Flora, and Molecular Methods
7 Bacteriology: Respiratory Tract
7.1 Lower Respiratory Specimens, CAP, and HAP Pathogens 7.2 Cystic Fibrosis Pathogens and Quantitative Reporting 7.3 Upper Respiratory: Pharyngitis, Otitis, Sinusitis, Antigen/Molecular
8 Bacteriology: Gastrointestinal Tract
8.1 Enteric Pathogens: Culture and Colony Morphology 8.2 Clostridioides difficile, Shiga Toxin, and Serotyping 8.3 Helicobacter pylori Detection and GI Pathogenicity
9 Bacteriology: Skin, Soft Tissue, and Bone
9.1 Skin, Soft Tissue, and Bone Pathogens 9.2 Bite Wounds and Zoonotic Infections 9.3 SST Pathogenicity and Virulence Mechanisms
10 Bacteriology: Genital Tract and Urine
10.1 Genital Flora and Vaginitis Pathogens 10.2 Neisseria gonorrhoeae, Chlamydia trachomatis, GBS, and Mycoplasma 10.3 Urinary Pathogens, Colony Counts, and Urinalysis Correlation
11 Bacteriology: Identification Methods
11.1 Colony Morphology and Rapid Presumptive Tests 11.2 Conventional Biochemicals and Commercial Kits 11.3 Automated Methods, MALDI-TOF MS, Molecular, and 16S Sequencing
12 Bacteriology: Antimicrobial Susceptibility and Resistance
12.1 Microbroth Dilution, Disk Diffusion, and Gradient Diffusion 12.2 Phenotypic Detection of Resistance 12.3 Antibiotic Classes, Intrinsic Resistance, and Genetic Markers
13 Bacteriology: Resistance Screening and Select Agents
13.1 MRSA/MSSA, VRE, ESBL/CRE Screening 13.2 BSL-3 Pathogens and Select-Agent Presumptive Identification 13.3 Laboratory Response Network and Select-Agent Pathogenicity
14 Mycobacteriology and Nocardia
14.1 Specimens, Major Pathogens, and Disease States 14.2 Acid-Fast Reaction, Colony Morphology, and Growth Characteristics 14.3 Identification Methods, Direct Molecular Detection, and TB Therapy
15 Virology
15.1 Respiratory, Vesicle, Meningitis, and GI Viruses 15.2 Hepatitis, HIV, and Immunocompromised-Host Viruses 15.3 Direct Detection Methods and HPV Cervical Screening
16 Parasitology
16.1 Blood, Tissue, and Brain Protozoa 16.2 Intestinal/Urogenital Protozoa and Helminths 16.3 Microscopy, Antigen/Molecular Detection, Insects and Arthropods
17 Mycology
17.1 Yeasts: Candida, Cryptococcus, and Malassezia 17.2 Dimorphic Fungi and Dermatophytes 17.3 Mucorales, Hyaline Molds, Pneumocystis, and Identification Methods
18 Serology
18.1 Immunoglobulin Response and Antigen-Antibody Methods 18.2 Viral Serodiagnosis: Hepatitis, EBV, HIV, CMV, Rubella, Measles 18.3 Treponema, Borrelia, and TB Infection Serodiagnosis
19 Laboratory Operations: Postanalytic Procedures and Quality
19.1 Documentation, Critical Values, Corrected Reports, and Public Health 19.2 Quality Control, Root-Cause Analysis, and POCT 19.3 Proficiency Testing, Competency, and Accreditation
20 Laboratory Operations: Safety, Mathematics, and Instrumentation
20.1 Biosafety, PPE, Bloodborne Pathogens, and SDS 20.2 Emergencies and Packaging/Transportation of Specimens 20.3 Laboratory Mathematics and Instrumentation
18.2 Viral Serodiagnosis: Hepatitis, EBV, HIV, CMV, Rubella, Measles
Key Takeaways Explain This Topic AI
Interpret hepatitis as a panel: HBsAg marks current HBV infection, anti-HBs marks immunity, anti-HBc distinguishes exposure from vaccine, IgM anti-HBc marks the acute/window period, and HBeAg tracks higher infectivity.
Anti-HAV IgM diagnoses acute hepatitis A; HCV antibody is a screen that must be followed by HCV RNA to confirm current infection.
Acute EBV: VCA IgM/IgG positive and EBNA negative; past EBV: VCA IgG and EBNA positive, VCA IgM negative; heterophile can be false-negative in children.
HIV screening is a fourth-generation antigen/antibody combo, then antibody differentiation, then NAAT if the differentiation assay is negative or indeterminate.
CMV IgM is limited by false positives and persistence; IgG avidity times primary infection, and plasma viral load is the better marker of CMV disease in transplant recipients.
Last updated: August 2026
18.2 Viral Serodiagnosis: Hepatitis, EBV, HIV, CMV, Rubella, Measles
Quick Answer: Read panels, not single markers. Acute HAV is anti-HAV IgM. HBV is HBsAg (current infection), anti-HBs (immunity), anti-HBc IgM/total (exposure, not vaccine), and HBeAg (higher infectivity). HCV antibody is a screen; RNA confirms current infection. Acute EBV is VCA IgM/IgG positive and EBNA negative; past EBV is VCA IgG plus EBNA. HIV is Ag/Ab combo, then differentiation, then NAAT if needed. CMV IgM is limited; IgG avidity times primary infection; viral load is better for transplant disease. Rubella and measles: IgM for acute disease, IgG for immunity.
Outline III.E.3 (guideline 2025-09-25 ) tests serodiagnosis, clinical significance, and epidemiology of hepatitis A/B/C, EBV, HIV, CMV, rubella, and measles . Virus biology and plasma viral-load matrices were Chapter 15. This section is what the antibodies and antigens mean when they come back as a panel. West Nile and other arbovirus encephalitis serology is SM-only (III.E.4) and is not M-tested.
Hepatitis A, B, and C
Hepatitis A is fecal–oral and never chronic. Anti-HAV IgM diagnoses acute infection. Anti-HAV IgG (or total anti-HAV after IgM has gone) marks immunity from infection or vaccine. Do not look for a chronic HAV carrier state.
Hepatitis B is the panel exam. Markers are not interchangeable.
- Marker What it detects Clinical meaning
- HBsAg HBV surface antigen Current infection, acute or chronic; persistence beyond 6 months defines chronic HBV
- Anti-HBs Antibody to surface antigen Immunity from resolved infection or from vaccine
- IgM anti-HBc IgM to core Acute HBV or the window when HBsAg has fallen and anti-HBs has not yet risen
Total / IgG anti-HBc Core antibody Exposure; present in recovered and chronic infection; not produced by vaccine
- HBeAg Hepatitis B e antigen Higher replication and infectivity
- Anti-HBe Antibody to e antigen Usually lower replication
Classic patterns to memorize cold:
Vaccinated : anti-HBs only. HBsAg negative, anti-HBc negative.
Acute HBV : HBsAg positive, IgM anti-HBc positive, total anti-HBc positive, anti-HBs negative.
Window : HBsAg negative, anti-HBs still negative, IgM anti-HBc positive . This is why isolated IgM anti-HBc is not “nothing.”
Chronic HBV : HBsAg positive for more than 6 months, total anti-HBc positive, IgM anti-HBc negative or low, anti-HBs negative. HBeAg versus anti-HBe then splits high versus lower infectivity.
Recovered : HBsAg negative, anti-HBc positive, anti-HBs positive.
Isolated anti-HBc : false-positive core antibody, window, occult HBV, or remote infection with waning anti-HBs. Do not call it vaccine immunity.
Hepatitis C screening is HCV antibody . Antibody does not prove viremia: it remains after spontaneous clearance and after cure. HCV RNA (NAAT) confirms current infection and is the test that changes management. Antibody-positive, RNA-negative means resolved or treated infection or a false-positive antibody—not a license to skip RNA. There is no HCV vaccine, so anti-HCV is never a “vaccinated” pattern.
Epidemiology still matters. HAV is food, water, and close contact. HBV is blood, sexual contact, and perinatal. HCV is blood, with injection-drug use the dominant current risk. Do not assign fecal–oral transmission to HBV or HCV on a serology item.
EBV: VCA, EBNA, and heterophile
Epstein–Barr virus causes infectious mononucleosis in adolescents and young adults and then persists for life. Serology times acute versus past infection; it does not replace plasma EBV PCR when a transplant patient is being monitored for PTLD (that viral-load use was Chapter 15).
VCA IgM : acute infection. Appears early and usually fades over weeks to a few months.
VCA IgG : appears in acute infection and lasts for life .
EBNA IgG : nuclear antigen antibody appears later (often 1–6 months). EBNA is negative in true acute IM and positive in past infection.
Heterophile antibody (Monospot / Paul–Bunnell): IgM that agglutinates sheep or horse red cells. It is not EBV-specific . It supports acute IM in older children and adults but is often false-negative in young children and can be false-positive in other illnesses.
- Pattern VCA IgM VCA IgG EBNA IgG Interpretation
- Acute IM Positive Positive or rising Negative Current primary EBV
- Past infection Negative Positive Positive Remote EBV, not acute IM
- Susceptible Negative Negative Negative No immunity
- Heterophile-negative child May still be VCA IgM positive — — Do not exclude EBV on Monospot alone in children
Reactivation and EA (early antigen) patterns appear in immunocompromised hosts; M still wants you to separate acute IM (EBNA negative) from past infection (EBNA positive) before you invent a fourth pattern.
HIV: combo, differentiation, NAAT
Adult screening uses a fourth-generation HIV-1/2 antigen/antibody combination immunoassay that detects IgM/IgG plus p24 antigen . p24 shortens the window relative to antibody-only tests. A reactive combo is not a final diagnosis.
CDC laboratory algorithm:
Reactive Ag/Ab combo.
HIV-1/HIV-2 antibody differentiation immunoassay.
If differentiation is negative or indeterminate, HIV-1 NAAT (RNA).
Acute (Fiebig) infection can be combo-reactive because of p24 while differentiation is still negative and NAAT is positive—that is true early HIV, not a random false positive. HIV-2 is uncommon in the United States but the differentiation step exists so you do not treat or counsel the wrong virus. Third-generation antibody-only EIAs miss the p24-only window. Do not diagnose HIV on a single rapid antibody device without the algorithm when the stem is a laboratory algorithm question. Plasma viral load monitors known infection; it is not the population screening test.
CMV, rubella, and measles
CMV IgM is a weak stand-alone test. It can be falsely positive (RF, heterologous IgM), can persist, and can reappear with reactivation. CMV IgG documents past infection and is the donor/recipient serostatus used to risk-stratify transplant patients (D+/R− is the highest primary-infection risk). IgG avidity times primary infection: low avidity supports recent primary infection (typically within about 3–4 months); high avidity supports past infection. In transplant recipients with fever, leukopenia, pneumonitis, or colitis, quantitative plasma CMV viral load is the disease and preemptive-therapy marker—not a rising IgM. Congenital CMV is diagnosed with neonatal urine or saliva PCR (and blood PCR), not with maternal IgG, which only proves the mother was ever infected.
Rubella IgM diagnoses acute infection in a compatible rash illness. Rubella IgG documents immunity, which is why prenatal panels order it. Congenital rubella syndrome uses infant IgM (fetal isotype) and persistent IgG; neonatal IgG alone may be maternal. Nonimmune pregnant patients need counseling and follow-up, not a measles-style outbreak PCR as the first immunity test.
Measles IgM, collected at or after rash onset (sensitivity rises after the first couple of days), supports acute measles together with NAAT on throat or NP and urine. Measles IgG documents immunity from vaccine or past disease. During an outbreak, IgM plus PCR and public-health notification matter more than a lone heterophile. Do not use EBV VCA to diagnose measles, and do not use measles IgG as an acute diagnostic in a rash that started yesterday.
Across this list the exam trick is the same: one marker is a fragment . HBsAg without anti-HBc cannot tell vaccine from infection. HCV antibody without RNA cannot tell cured from viremic. VCA IgG without EBNA cannot tell acute from past. HIV combo without differentiation/NAAT is a screen. CMV IgM without viral load does not diagnose transplant disease.